Glioblastoma multiforme (GBM), the most common primary brain tumour, continues to have a dismal prognosis. The standard initial treatment for GBM is surgical resection along with postoperative adjuvant therapy, including temozolomide, concomitant with 60 Gy of radiation therapy (RT). However, most patients eventually relapse and long-term survival remains elusive. Thus, novel therapeutic modalities for GBM are being explored, and different types of immune-mediated approaches have been preclinically and clinically evaluated in phase I and II trials. However, these GBM clinical trials face significant limitations in terms of their assessment of tumour progression and protocol setting. A critical and comprehensive review of how GBM trials should be conducted is required with a focus on how progression can be defined and clinical benefits can be evaluated following the administration of cancer vaccines.
Controversies in Clinical Trials of Cancer Vaccines for Glioblastoma: Mizuhiko Terasaki, Kenta Murotani, Yoshitaka Narita, Ryo Nishikawa, Tetsuro Sasada, Akira Yamada, Kyogo Itoh and Motohiro Morioka
Last date updated on July, 2014